ELIMINATING VIRUSES

We are developing best-in-class treatment and prophylaxis agents for HIV and HBV, and pursuing an HIV cure.

OUR APPROACH

MULTI-MODALITY NANOMEDICINE

Nano-medicine is the foundation of our small molecule ULA platform and our next generation LNP delivery of gene-editing therapeutics.

HIV remains a major global health issue

1200000

Estimated infections in the US

40000000

Estimated infections worldwide

>$ 30000000000

Annual drug sales in HIV category

900 %

Increase in healthcare costs for HIV+ vs HIV-

1 in 4

Patients are fully adherent to treatment

9 out of 10

Prefer long-acting therapy to daily oral therapy

99 %

Risk-reduction when HIV PrEP is taken as prescribed

ULTRA-LONG-ACTING NANOMEDICINE

Exavir’s small molecule platform technology enables ultra-long-acting release for potentially once-every-six-months and longer dosing

EXAVIR NANOCRYSTALS

Exavir programs cover multiple nodes in the HIV life-cycle for all-ultra-long-acting combination therapy regimens

Read More

A CURE IS POSSIBLE

Advances in precision gene-editing have enabled the possibility of a cure for HIV.

We are developing next generation nanoparticles for multiple gene-editing based strategies.

EXAVIR LIPID NANOPARTICLES

Read More